SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
SELLAS Life Sciences Group, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$10.49+0.51 (+5.11%)
Close on Oct 19, 2026
- Market cap
- $1.98B
- P/E (TTM)
- –
- Dividend yield
- –
SELLAS Life Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Market Cap | $2.12B | $166.30M |
| Enterprise Value | $1.98B | $88.19M |
| PB Ratio | 15.39 | 2.03 |
| P/TBV Ratio | 15.61 | 2.29 |
Income (trailing twelve months)
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Operating Income | -$35.22M | -$21.40M |
| Net Income | -$32.46M | -$22.46M |
| EBITDA | -$35.22M | -$16.91M |
| EPS (Diluted) | -$0.21 | -$0.83 |
Returns
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -39.6% | -53.2% |
| Return on Assets (ROA) | -36.5% | -40.9% |
| Return on Invested Capital (ROIC) | -85609.3% | -32.4% |
| Return on Capital Employed (ROCE) | -25.6% | -38.1% |
Balance sheet
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $138.34M | $61.43M |
| Net Cash (Debt) | $138.34M | $15.35M |
| Net Cash Per Share | $0.69 | $0.66 |
| Equity (Book Value) | $137.66M | $49.09M |
| Book Value Per Share | $0.68 | $1.37 |
| Tangible Book Value | $135.74M | $23.52M |
| Working Capital | $134.94M | $76.81M |
Financial position
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Current Ratio | 18.83 | 3.34 |
| Quick Ratio | 18.28 | 2.44 |
Cash flow (trailing twelve months)
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$28.42M | -$12.35M |
Efficiency
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Profits Per Employee | -$2.50M | -$703.34K |
| Employee Count | 13 | 74 |
Dividends and yields
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Earnings Yield | -1.53% | -23.3% |
Shares
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 201,946,000 | 58,127,000 |
| Shares Change (YoY) | 86.1% | 10.9% |
| Shares Change (QoQ) | 11.4% | 0.54% |
| Float | 198,326,000 | 49,136,700 |
| Shares Held by Insiders | 1.79% | 11.6% |
| Shares Held by Institutions | 36.5% | 59.4% |
Scores
| Measure | SELLAS Life Sciences | Industry median |
|---|---|---|
| Altman Z-Score | 162.01 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from SELLAS Life Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.